Skip to main content

MARSHALL WACE, LLP

Position in NVS — Novartis AG

CIK 1318757 LONDON, X0

Position in NVS

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$49,194,053
-$46,398,938 QoQ
Shares Held
322,056
-53.6% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Dec 2021
16 quarters on record
Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Common Shares in NVS Over Time

Shares Held

Position Value (USD)

Derivatives in NVS

reported options exposure · as of Sep 30, 2025
CallValue
$51,296
CallShares
400
PutValue
$89,768
PutShares
700

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,860,542,672 across 13 Drug Manufacturers - General names. NVS ranks #10 (1.7% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in NVS

Export CSV
18 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $49,194,053 322,056
2025-12-31 $95,592,991 693,356
2025-09-30 $149,881,397 1,168,757
2025-09-30 $51,296 400
2025-09-30 $89,768 700
2025-06-30 $173,263,811 1,431,814
2025-03-31 $159,725,756 1,432,775
2024-12-31 $8,628,088 88,666
2024-03-31 $12,695,522 131,247
2023-12-31 $43,651,552 432,322
2023-09-30 $107,670,297 1,057,042
2023-06-30 $105,179,703 1,042,312
2023-03-31 $122,006,352 1,326,156
2022-12-31 $73,872,116 814,287
2022-09-30 $66,337,043 872,741
2022-06-30 $77,573,096 917,699
2022-03-31 $59,552,502 678,661
2021-12-31 $13,625,463 155,773